|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-3-12
|
|
pubmed:abstractText |
Radical cystectomy represents the treatment of choice for muscle infiltrative bladder carcinoma. Adjuvant chemotherapy has been used to improve outcome after cystectomy. We report results in a prospective cohort of patients at high risk for relapse who were treated with the combination of paclitaxel and carboplatin as adjuvant treatment following cystectomy for muscle invasive bladder cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
171
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1467-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15017199-Adult,
pubmed-meshheading:15017199-Aged,
pubmed-meshheading:15017199-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15017199-Carboplatin,
pubmed-meshheading:15017199-Chemotherapy, Adjuvant,
pubmed-meshheading:15017199-Female,
pubmed-meshheading:15017199-Follow-Up Studies,
pubmed-meshheading:15017199-Humans,
pubmed-meshheading:15017199-Male,
pubmed-meshheading:15017199-Middle Aged,
pubmed-meshheading:15017199-Paclitaxel,
pubmed-meshheading:15017199-Prospective Studies,
pubmed-meshheading:15017199-Survival Rate,
pubmed-meshheading:15017199-Urinary Bladder Neoplasms
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group.
|
|
pubmed:affiliation |
Department of Clinical Therapeutics and Urology, University of Athens, School of Medicine, Greece.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
